Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility

  • STATUS
    Recruiting
  • End date
    Mar 19, 2023
  • participants needed
    360
  • sponsor
    Centre Hospitalier Universitaire, Amiens
Updated on 19 July 2021
ejection fraction
beta blockers
shock

Summary

Several data emphasize the relation between tachycardia (>90/min) and high mortality during septic shock. The investigators previously demonstrated the high mortality associated with hypercontractility, tachycardia and the presence of a left ventricular obstruction. A severe hypovolemia, a hyper adrenergic stimulation or a severe vasoplegia can all explain this relation between tachycardia, hypercontractility and the mortality during septic shock.

Landiolol is another short-term acting beta-blocker with a half-life of 4 minutes without any beta 2 activity or membrane stabilizing effect. The landiolol has been used in critically ill patients to control supraventricular tachycardia but not in this context of tachycardia and septic shock. The investigators hypothesize that landiolol by reducing the heart rate may improve the survival of patients treated for a septic shock and presenting with an hypercontractility state.

Details
Condition beta blocker, septic shock, beta-blockers, Mortality During Septic Shock, beta-Adrenergic Blocking Agents, Arrhythmia, beta adrenergic antagonists, Fast Heart Rate (Tachycardia), beta-blocker, beta-adrenergic antagonist, Toxic Shock Syndrome, Dysrhythmia, Tachycardia, beta blockers
Treatment Echocardiography, Landiolol
Clinical Study IdentifierNCT04748796
SponsorCentre Hospitalier Universitaire, Amiens
Last Modified on19 July 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 18 years old
Patient admitted for a septic shock (according to the SEPSIS3 definition: sepsis with persisting hypotension (MAP<65mmHg or SAP <90mmHg) requiring vasopressors to maintain MAP>65mmHg and having a serum lactate level >2 mmol/L
Patient who received at least 30ml/kg of fluid and absence of fluid responsiveness
Left ventricular ejection fraction >65% (visual or Simpson method using echocardiography)
Tachycardia >100 bpm in sinus rhythm with a MAP 65mmHg for more than 1 hour
Patient receiving invasive mechanical ventilation
Patients adapted to the ventilator under sedation and analgesia
Written informed consent
Patient covered by French national health insurance

Exclusion Criteria

Patients with inclusion criteria already present for more than 36 hours
Patient treated with Dobutamine, adrenaline or isoprenaline
Patient currently treated with beta blockers (previous home betablocker treatment is not an exclusion criteria)
Supra ventricular (atrial fibrillation or flutter) or ventricular arrhythmias
Patients with any form of cardiac pacing
Sick sinus syndrome
Severe atrioventricular (AV) nodal conductance disorders (without pacemaker): 2nd or 3rd degree AV block
Known pulmonary hypertension
ScVO2 <70%
Moribund
Cardiac arrest
Non-treated phaeochromocytoma
Acute asthmatic attack
Pregnant or breastfeeding woman
Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)
Age <18 years
Hypersensitivity to the active substance or to any of the excipients
Severe bradycardia (less than 50 beats per minute)
Cardiogenic shock
Severe hypotension
Decompensated heart failure when considered not related to the arrhythmia
Severe, uncorrectable metabolic acidosis
Presence of significant bleeding, or
Acute respiratory distress defined by increased oxygen dependency, polypnea > 30 /min, signs of struggle (pulling, thoraco-abdominal sway) if the patient is not intubated and ventilated
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note